Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder. For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).
Tonix Pharmaceuticals is developing next-generation medicines to help important public health challenges.
Tonix's lead drug candidate was granted Breakthrough Therapy designation by the FDA for the treatment of posttraumatic stress disorder (PTSD).Learn more
• July 16, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced that the U.S. Food and Drug Administration (FDA)…Read more
Our experienced team has a strong track record of success in drug approvals and value creation.View Management
Tonix's lead product candidate, Tonmya, is being developed for the treatment of PTSD.View Pipeline
Tonix is developing innovative pharmaceutical products to address important public health challenges, with two programs focusing on posttraumatic stress disorder (PTSD). PTSD is a serious condition characterized by chronic disability, inadequate treatment options, and overall high utilization of healthcare services creating significant economic burden. Other development programs include TNX-801, a potential smallpox-preventing vaccine.Learn more about tonix